[The global consensus statement 2013 on menopausal hormone therapy].
More than ten years after the publication of the "Women's Health Initiatives" (WHI) study, a global consensus statement on menopausal hormone replacement therapy (HRT) has been edited by an expert committee, composed by all the international menopausal societies. This global consensus has been published in April 2013 in the journal Climacteric. In conclusion, HRT has to be an individual decision, weighing up benefits and risks and it should not be prescribed for the first time in women older than 60 years or more than ten years after the onset of menopause. Dose and duration of HRT are individual and the indication has to be reevaluated annually. HRT is contraindicated in breast cancer survivors.
Unité de médecine de reproduction, Département de gynécologie-obstétrique, CHUV, 1011 Lausanne. dorothea.wunder@chuv.ch
Dorothea
D
Wunder
Thierry D
TD
Pache
D003245:Consensus Statements as Topic; D005260:Female; D020249:Hormone Replacement Therapy / Q000592:standards*; D006801:Humans; D017698:Postmenopause